Waters Expands Accessibility to High Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System
January 22 2019 - 8:30AM
Business Wire
As the Number of Analytical Monitoring Tests
for Biopharmaceuticals Skyrockets, Waters Builds Intelligence into
a Fit-for-Purpose System
Waters Corporation (NYSE:WAT) today introduced the
BioAccord™ System, a purposefully designed liquid
chromatography-mass spectrometry (LC-MS) solution that will expand
access to high-resolution time-of-flight mass spectrometry
capabilities to more scientists. The BioAccord System promises to
move routine monitoring out of centralized MS labs and into the
hands of more scientists by enabling more effective analysis of
biotherapeutic protein attributes across development and within
quality control organizations.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190122005306/en/
Waters Expands Accessibility to High
Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma
System (Photo: Business Wire)
"The pace of innovation in the biopharmaceutical industry is
accelerating, and with it, the monitoring requirements for
biotherapeutics are growing exponentially," said Chris O'Connell,
Chairman and CEO, Waters Corporation. "The inherent complexity of
these therapies, combined with rising regulatory standards, are
driving more intensive and widespread testing requirements. Waters
designed the BioAccord System as a fit-for-purpose LC-MS
biopharmaceutical solution to deliver rich mass spectrometry data
for improved productivity and effective decision-making."
The BioAccord System pairs ACQUITYTM UPLC™ I-Class Plus with the
newly-developed ACQUITY RDa™ Detector featuring SmartMS™. This
system offers new levels of user experience with automated setup
and self diagnosis delivered through an intuitive user interface,
all within a surprisingly small footprint. Powered by UNIFI™,
Waters’ compliance-ready LC-MS informatics platform, the BioAccord
System has been optimized for intact protein, released glycan, and
peptide monitoring applications, and streamlined by the use of
Waters' application-specific chemistries and consumables kits.
The first public exhibition of the BioAccord System will take
place at the Well Characterized Biopharmaceutical Conference (WCBP)
in Washington D.C. On Tuesday, January 29, at WCBP, Waters will
sponsor a lunch seminar in the Palm Court Room at the Mayflower
Hotel from 12:45 – 1:45 p.m. titled: High Performance LCMS Analysis
in Biopharma: From Molecular Characterization to Routine Monitoring
featuring Dr. John Gebler, Director, Biopharmaceutical, Waters
Corporation. Guest speaker, Dr. Mellisa M. Ly, Principal Scientist
from Pfizer, Inc. will expand on the topic presenting,
Characterizing and Monitoring Quality Attributes in Monoclonal
Antibodies using a High Resolution, Small Footprint LC-MS
System.
Additionally, customers are invited to visit
www.waters.com/bioaccord for a deeper understanding of the new
BioAccord LC-MS system.
The BioAccord System is currently available for customer
shipments worldwide.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), the world's leading
specialty measurement company, has pioneered chromatography, mass
spectrometry, and thermal analysis innovations serving the life,
materials, and food sciences for more than 60 years. With
approximately 7,000 employees worldwide, Waters operates directly
in 31 countries, including 15 manufacturing facilities, and with
products available in more than 100 countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190122005306/en/
Jeff Tarmy508-482-2268jeff_tarmy@waters.com
Waters (NYSE:WAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2023 to Apr 2024